“Overactive Bladder Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Overactive Bladder Market.
The Overactive Bladder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Overactive Bladder Pipeline Report:
-
Companies across the globe are diligently working toward developing novel Overactive Bladder treatment therapies with a considerable amount of success over the years.
-
Overactive Bladder companies working in the treatment market are Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others, are developing therapies for the Overactive Bladder treatment
-
Emerging Overactive Bladder therapies in the different phases of clinical trials are- ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others are expected to have a significant impact on the Overactive Bladder market in the coming years.
-
In December 2024, FemPulse™ announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate its EVANESCE II pivotal clinical trial in female patients with overactive bladder (OAB). OAB represents the first use of FemPulse’s patented platform for female health.
-
In October 2024, Vensica Medical ("Vensica"), an innovative urology therapeutics company, today announced the successful completion of an $11 million funding round. The investment will support the company's upcoming Phase 2 clinical trials in the United States and Europe for its groundbreaking treatment of overactive bladder (OAB), utilizing botulinum toxin A (Xeomin®) delivered through a proprietary, needle-free device.
-
In April 2024, SpineX has completed patient enrollment for its CONTINENCE clinical trial (NCT05301335), which evaluates the Scone neuromodulation device for treating neurogenic bladder, often associated with conditions like multiple sclerosis (MS), stroke, or spinal cord injury. Conducted at multiple sites across the U.S., Canada, and India, the study targets adults experiencing overactive bladder symptoms due to these neurological conditions. Researchers at SpineX are optimistic that participants in the trial will experience notable enhancements in self-reported symptoms linked to neurogenic bladder.
Overactive Bladder Overview
Overactive Bladder (OAB) is a condition characterized by a frequent and urgent need to urinate, often accompanied by incontinence. It occurs when the bladder muscles contract involuntarily, leading to an overactive or over-responsive bladder. Symptoms include frequent urination, urgency, and sometimes leaking urine, which can significantly impact daily life and quality of life. OAB can affect both men and women, and its causes may include age, neurological conditions, or bladder infections. Treatment options include lifestyle changes, medications, and in some cases, medical devices or surgery.
Get a Free Sample PDF Report to know more about Overactive Bladder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight
Emerging Overactive Bladder Drugs Under Different Phases of Clinical Development Include:
-
ARD-380: Aardvark Therapeutics
-
URB937: Exxel Pharma
-
Botulax: Hugel
-
IMB-115: Imbrium Therapeutics
-
TAC-302: Taiho Pharmaceutical
-
URO-902: Sumitovant Biopharma
-
DA-8010: Dong-A ST
Overactive Bladder Route of Administration
Overactive Bladder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Overactive Bladder Molecule Type
Overactive Bladder Products have been categorized under various Molecule types, such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Overactive Bladder Pipeline Therapeutics Assessment
-
Overactive Bladder Assessment by Product Type
-
Overactive Bladder By Stage and Product Type
-
Overactive Bladder Assessment by Route of Administration
-
Overactive Bladder By Stage and Route of Administration
-
Overactive Bladder Assessment by Molecule Type
-
Overactive Bladder by Stage and Molecule Type
DelveInsight's Overactive Bladder Report covers around 15+ products under different phases of clinical development like
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
-
Route of Administration
Further Overactive Bladder product details are provided in the report. Download the Overactive Bladder pipeline report to learn more about the emerging Overactive Bladder therapies
Some of the key companies in the Overactive Bladder Therapeutics Market include:
Key companies developing therapies for Overactive Bladder are - Astellas Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharma, Inc., Medtronic, Pfizer Inc, Teva Pharma, AbbVie Inc, Allergan, Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical, and others.
Overactive Bladder Pipeline Analysis:
The Overactive Bladder pipeline report provides insights into
-
The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
-
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
-
Overactive Bladder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Overactive Bladder drugs and therapies
Overactive Bladder Pipeline Market Drivers
-
Prevalence of urinary incontinence, approval of generics, growth in the number of product launches are some of the important factors that are fueling the Overactive Bladder Market.
Overactive Bladder Pipeline Market Barriers
-
However, lack of diagnosis and information about OAB, side effects associated with the current treatment options and other factors are creating obstacles in the Overactive Bladder Market growth.
Scope of Overactive Bladder Pipeline Drug Insight
-
Coverage: Global
-
Key Overactive Bladder Companies: Aardvark Therapeutics, Exxel Pharma, Hugel, Imbrium Therapeutics, Taiho Pharmaceutical, Sumitovant Biopharma, Dong-A ST, and others
-
Key Overactive Bladder Therapies: ARD-380, URB937, Botulax, IMB-115, TAC-302, URO-902, DA-8010, and others
-
Overactive Bladder Therapeutic Assessment: Overactive Bladder current marketed and Overactive Bladder emerging therapies
-
Overactive Bladder Market Dynamics: Overactive Bladder market drivers and Overactive Bladder market barriers
Request for Sample PDF Report for Overactive Bladder Pipeline Assessment and clinical trials
Table of Contents
1. Overactive Bladder Report Introduction
2. Overactive Bladder Executive Summary
3. Overactive Bladder Overview
4. Overactive Bladder- Analytical Perspective In-depth Commercial Assessment
5. Overactive Bladder Pipeline Therapeutics
6. Overactive Bladder Late Stage Products (Phase II/III)
7. Overactive Bladder Mid Stage Products (Phase II)
8. Overactive Bladder Early Stage Products (Phase I)
9. Overactive Bladder Preclinical Stage Products
10. Overactive Bladder Therapeutics Assessment
11. Overactive Bladder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Overactive Bladder Key Companies
14. Overactive Bladder Key Products
15. Overactive Bladder Unmet Needs
16 . Overactive Bladder Market Drivers and Barriers
17. Overactive Bladder Future Perspectives and Conclusion
18. Overactive Bladder Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
